PMID- 29267258
OWN - NLM
STAT- MEDLINE
DCOM- 20180809
LR  - 20211204
IS  - 1643-3750 (Electronic)
IS  - 1234-1010 (Print)
IS  - 1234-1010 (Linking)
VI  - 23
DP  - 2017 Dec 21
TI  - Plasma Long Non-Coding RNA (lncRNA) GAS5 is a New Biomarker for Coronary Artery 
      Disease.
PG  - 6042-6048
AB  - Our study aimed to investigate the diagnostic value of long non-coding RNA 
      (lncRNA) GAS5 for coronary artery disease (CAD) and to explore the mechanism of 
      the role of GAS5 in CAD. A total of 30 patients with CAD were selected from 
      January 2015 to January 2017 in The First Hospital of Tianmen. In addition, 30 
      healthy individuals were selected as a control group, and patients with various 
      other types of cardiovascular diseases were also selected. Expression of GAS5 in 
      plasma of all participants was detected by quantitative real-time PCR. Receiver 
      operating characteristic (ROC) curve analysis was performed to investigate the 
      diagnostic value of GAS5 for CAD. Levels of mammalian target of rapamycin (mTOR) 
      and phospho-mTOR (p-mTOR) in human primary coronary artery endothelial cells 
      (HCAECs) were detected by western blotting. Compared with normal healthy people, 
      expression level of lncRNA Novlnc6 was significantly reduced in patients with CAD 
      and diabetes mellitus, but not in patients with other types of cardiovascular 
      diseases, such as hypertension, abnormal aortic aneurysm, viral myocarditis. In 
      addition, the expression level of GAS5 was significantly lower in patients with 
      CAD compared to patients with diabetes mellitus. ROC curve analysis showed that 
      GAS5 may serve as a promising biomarker for CAD. GAS5 knockdown and 
      overexpression showed no significant effect on the level of mTOR) in HCAECs. 
      However, GAS5 knockdown significantly increased the level of phospho-mTOR 
      (p-mTOR), and GAS5 overexpression significantly decreased the level of p-mTOR. 
      Treatment with mTOR inhibitor and activator showed no significant effect on 
      expression of GAS5 in HCAECs. GAS5 plays a role as upstream regulator of the mTOR 
      pathway to participate in the development of CAD. GAS5 was specifically 
      downregulated in patients with CAD, and it may serve as a promising biomarker for 
      CAD.
FAU - Yin, Qiong
AU  - Yin Q
AD  - Department of Cardiology, The First People's Hospital of Tianmen, Tianmen, Hubei, 
      China (mainland).
FAU - Wu, Anshuang
AU  - Wu A
AD  - Department of Cardiology, The First People's Hospital of Tianmen, Tianmen, Hubei, 
      China (mainland).
FAU - Liu, Manhua
AU  - Liu M
AD  - Department of Cardiology, The First People's Hospital of Tianmen, Tianmen, Hubei, 
      China (mainland).
LA  - eng
PT  - Journal Article
DEP - 20171221
PL  - United States
TA  - Med Sci Monit
JT  - Medical science monitor : international medical journal of experimental and 
      clinical research
JID - 9609063
RN  - 0 (Biomarkers)
RN  - 0 (GAS5 long non-coding RNA, human)
RN  - 0 (RNA, Long Noncoding)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers/blood
MH  - Case-Control Studies
MH  - Cell Proliferation/physiology
MH  - Cells, Cultured
MH  - Coronary Artery Disease/*blood/*genetics/pathology
MH  - Coronary Vessels/metabolism/*surgery
MH  - Diabetes Mellitus/blood/genetics
MH  - Down-Regulation
MH  - Endothelial Cells/metabolism
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - RNA, Long Noncoding/*blood/genetics/metabolism
MH  - Real-Time Polymerase Chain Reaction
MH  - TOR Serine-Threonine Kinases/blood
PMC - PMC5747294
EDAT- 2017/12/22 06:00
MHDA- 2018/08/10 06:00
PMCR- 2017/12/21
CRDT- 2017/12/22 06:00
PHST- 2017/12/22 06:00 [entrez]
PHST- 2017/12/22 06:00 [pubmed]
PHST- 2018/08/10 06:00 [medline]
PHST- 2017/12/21 00:00 [pmc-release]
AID - 907118 [pii]
AID - 10.12659/msm.907118 [doi]
PST - epublish
SO  - Med Sci Monit. 2017 Dec 21;23:6042-6048. doi: 10.12659/msm.907118.